Bradykinin type 2 receptor BE1 genotype influences bradykinin-dependent vasodilation during angiotensin-converting enzyme inhibition

Hypertension

Volumn 51, Issue 2 PART 2, 2008, Pages 454-459

  Van Guilder, Gary P ^a   Pretorius, Mias ^a,b   Luther, James M ^a   Byrd, J Brian ^a   Hill, Kevin ^a   Gainer, James V ^a,b   Brown, Nancy J ^a  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Angiotensin converting enzyme; Bradykinin; Genotype; Plasminogen activators; Vasodilation

Indexed keywords

BRADYKININ; BRADYKININ B2 RECEPTOR; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRILAT; METHACHOLINE; NITROPRUSSIDE SODIUM; TISSUE PLASMINOGEN ACTIVATOR;

ADULT; BLOOD PRESSURE; BLOOD VESSEL REACTIVITY; BODY MASS; CONFERENCE PAPER; CONTROLLED STUDY; ENZYME RELEASE; FEMALE; FOREARM BLOOD FLOW; GENE FREQUENCY; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN DEGRADATION; STATISTICAL SIGNIFICANCE; SYSTOLIC BLOOD PRESSURE; VASCULAR RESISTANCE; VASODILATATION;

ADULT; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; BLOOD PRESSURE; BRADYKININ; DRUG SYNERGISM; ENALAPRILAT; ENDOTHELIUM, VASCULAR; FEMALE; FOREARM; GENOTYPE; HUMANS; INJECTIONS, INTRA-ARTERIAL; MALE; METHACHOLINE CHLORIDE; NITROPRUSSIDE; POLYMORPHISM, GENETIC; RECEPTOR, BRADYKININ B2; REGIONAL BLOOD FLOW; SEX FACTORS; TISSUE PLASMINOGEN ACTIVATOR; VASCULAR RESISTANCE; VASODILATION; VASODILATOR AGENTS;

EID: 38549114518     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.107.102574     Document Type: Conference Paper

References (27)

1. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. The Acute Infarction Ramipril Efficacy (AIRE) Study investigators. Lancet. 1993;342:821-828.
2. Pfeffer MA, Braunwald E, Moye LA, Basta L, Brown EJ Jr, Cuddy TE, Davis BR, Geltman EM, Goldman S, Flaker GC. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the Survival and Ventricular Enlargement Trial. The SAVE investigators. N Engl J Med. 1992;327:669-677.
3. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study investigators. N Engl J Med. 2000;342:145-153.
4. Kovacs I, Toth J, Tarjan J, Koller A. Correlation of flow mediated dilation with inflammatory markers in patients with impaired cardiac function. Beneficial effects of inhibition of ACE. Eur J Heart Fail. 2006;8:451-459.
5. Nakamura M, Funakoshi T, Arakawa N, Yoshida H, Makita S, Hiramori K. Effect of angiotensin-converting enzyme inhibitors on endothelium-dependent peripheral vasodilation in patients with chronic heart failure. J Am Coll Cardiol. 1994;24:1321-1327.
6. Pretorius M, Murphey LJ, McFarlane JA, Vaughan DE, Brown NJ. Angiotensin-converting enzyme inhibition alters the fibrinolytic response to cardiopulmonary bypass. Circulation. 2003;108:3079-3083.
7. Mancini GB, Henry GC, Macaya C, O'Neill BJ, Pucillo AL, Carere RG, Wargovich TJ, Mudra H, Luscher TF, Klibaner MI, Haber HE, Uprichard AC, Pepine CJ, Pitt B. Angiotensin-converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease. The Trend (Trial on Reversing Endothelial Dysfunction) study. Circulation. 1996;94:258-265.
8. Vaughan DE, Rouleau JL, Ridker PM, Arnold JM, Menapace FJ, Pfeffer MA. Effects of ramipril on plasma fibrinolytic balance in patients with acute anterior myocardial infarction. Circulation. 1997;96:442-447.
9. Gainer JV, Morrow JD, Loveland A, King DJ, Brown NJ. Effect of bradykinin-receptor blockade on the response to angiotensin-converting-enzyme inhibitor in normotensive and hypertensive subjects. N Engl J Med. 1998;339:1285-1292.
10. Witherow FN, Dawson P, Ludlam CA, Fox KA, Newby DE. Marked bradykinin-induced tissue plasminogen activator release in patients with heart failure maintained on long-term angiotensin-converting enzyme inhibitor therapy. J Am Coll Cardiol. 2002;40:961-966.
11. Pretorius M, Rosenbaum D, Vaughan DE, Brown NJ. Angiotensin-converting enzyme inhibition increases human vascular tissue-type plasminogen activator release through endogenous bradykinin. Circulation. 2003;107:579-585.
12. Marcic B, Deddish PA, Jackman HL, Erdos EG. Enhancement of bradykinin and resensitization of its B2 receptor. Hypertension. 1999;33:835-843.
13. Erdos EG. Kinins, the long march-a personal view. Cardiovasc Res. 2002;54:485-491.
14. 2-bradykinin receptor. New tools in assessing a genetic risk for bradykinin-associated diseases. Immunopharmacology. 1996;33:32-35.
15. 2-bradykinin receptor gene. Hum Genet. 1996;97:688-689.
16. 2-bradykinin receptor gene and its transcript in normal subjects and patients with C1 inhibitor deficiency. J Allergy Clin Immunol. 1997;99:134-146.
17. Dhamrait SS, Payne JR, Li P, Jones A, Toor IS, Cooper JA, Hawe E, Palmen JM, Wootton PT, Miller GJ, Humphries SE, Montgomery HE. Variation in bradykinin receptor genes increases the cardiovascular risk associated with hypertension. Eur Heart J. 2003;24:1672-1680.
18. Hallberg P, Lind L, Michaelsson K, Karlsson J, Kurland L, Kahan T, Malmqvist K, Ohman KP, Nystrom F, Melhus H. B2 bradykinin receptor (B2BKR) polymorphism and change in left ventricular mass in response to antihypertensive treatment: Results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA) Trial. J Hypertens. 2003;21:621-624.
19. Brull D, Dhamrait S, Myerson S, Erdmann J, Woods D, World M, Pennell D, Humphries S, Regitz-Zagrosek V, Montgomery H. Bradykinin B2BKR receptor polymorphism and left-ventricular growth response. Lancet. 2001;358:1155-1156.
20. Pretorius MM, Gainer JV, Van Guilder GP, Coelho EB, Luther JM, Fong P, Rosenbaum DD, Malave HA, Yu C, Ritchie MD, Vaughan DE, Brown NJ. The bradykinin type 2 receptor BE1 polymorphism and ethnicity influence systolic blood pressure and vascular resistance. Clin Pharmacol Ther. In Press.
21. Van Guilder GP, Hoetzer GL, Smith DT, Irmiger HM, Greiner JJ, Stauffer BL, DeSouza CA. Endothelial t-PA release is impaired in overweight and obese adults but can be improved with regular aerobic exercise. Am J Physiol Endocrinol Metab. 2005;289:E807-E813.
22. Chaplin H Jr, Mollison PL. Correction for plasma trapped in the red cell column of the hematocrit. Blood. 1952;7:1227-1238.
23. Labinjoh C, Newby DE, Pellegrini MP, Johnston NR, Boon NA, Webb DJ. Potentiation of bradykinin-induced tissue plasminogen activator release by angiotensin-converting enzyme inhibition. J Am Coll Cardiol. 2001;38:1402-1408.
24. Hoetzer GL, Stauffer BL, Irmiger HM, Ng M, Smith DT, DeSouza CA. Acute and chronic effects of oestrogen on endothelial tissue-type plasminogen activator release in postmenopausal women. J Physiol. 2003;551:721-728.
25. Pretorius M, Luther JM, Murphey LJ, Vaughan DE, Brown NJ. Angiotensin-converting enzyme inhibition increases basal vascular tissue plasminogen activator release in women but not in men. Arterioscler Thromb Vasc Biol. 2005;25:2435-2440.
26. Rubio-Gayosso I, Garcia-Ramirez O, Gutierrez-Serdan R, Guevara-Balcazar G, Munoz-Garcia O, Morato-Cartajena T, Zamora-Garza M, Ceballos-Reyes G. Testosterone inhibits bradykinin-induced intracellular calcium kinetics in rat aortic endothelial cells in culture. Steroids. 2002;67:393-397.
27. Weir MR, Gray JM, Paster R, Saunders E. Differing mechanisms of action of angiotensin-converting enzyme inhibition in black and white hypertensive patients. The trandolapril multicenter study group. Hypertension. 1995;26:124-130.